Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Combination Product: Ravulizumab OBDS
(Ultomiris (TN))		[1] Ravulizumab (Ultomiris)[1] Ravulizumab (Ultomiris (TN)) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬
2Ravulizumab
(Ultomiris (TN))		[1] Ravulizumab (Ultomiris)[1] Ravulizumab (Ultomiris (TN)) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[7] 2, 11, 13, 50, 62, 66, 109 💬
3Ultomiris[1] Ravulizumab (Ultomiris)[1] Ravulizumab (Ultomiris (TN)) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[6] 2, 11, 13, 50, 62, 66 💬
4ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO[1] Ravulizumab (Ultomiris)[1] Ravulizumab (Ultomiris (TN)) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬
5Ultomiris 1,100 mg/11 mL[1] Ravulizumab (Ultomiris)[1] Ravulizumab (Ultomiris (TN)) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 11 💬
6Ultomiris 300 mg/30 ml[1] Ravulizumab (Ultomiris)[1] Ravulizumab (Ultomiris (TN)) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 66 💬
7Ultomiris 300mg/30ml[1] Ravulizumab (Ultomiris)[1] Ravulizumab (Ultomiris (TN)) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬
8ULTOMIRIS ™ (ravulizumab-cwvz)[1] Ravulizumab (Ultomiris)[1] Ravulizumab (Ultomiris (TN)) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 62 💬
9ULTOMIRIS®[1] Ravulizumab (Ultomiris)[1] Ravulizumab (Ultomiris (TN)) 💬 [1] C5 💬 [11] Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬[1] 13 💬